- Molecular NameOlopatadine
- SynonymNA
- Weight337.419
- Drugbank_IDDB00768
- ACS_NO113806-05-6
- Show 3D model
- LogP (experiment)3.862
- LogP (predicted, AB/LogP v2.0)3.75
- pkaN/A
- LogD (pH=7, predicted)1.25
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)-3.06
- LogSw (predicted, AB/LogsW2.0)0.12
- Sw (mg/ml) (predicted, ACD/Labs)0.29
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds5
- TPSA49.77
- StatusFDA approved
- AdministrationOphthalmic, intranasal, oral
- PharmacologyAn antihistamine and mast cell stabilizer, sold as a prescription eye drop
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmOlopatadine is metabolized via oxidative N-demethylation and to via N-oxidation. After oral administration of olopatadine hydrochloride to rats and dogs, these metabolites were produced in very small quantities and the major component in plasma was the unchanged drug. In addition, the urinary excretion of unchanged drug after oral administration of olopatadine hydrochloride to rats, dogs and humans was 27.3, 51.6 and 58.7%, respectively
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityHeadaches have been reported at an incidence of 7%. The following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion. Some of these events were similar to the underlying disease being studied.
- LD50 (rat)N/A
- LD50 (mouse)N/A